Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Dexamethasone Sodium Phosphate in Refractory Multiple Myeloma: NCT07138209 Clinical Landscape Report 2026
15 October 2026
NCT07138209 clinical landscape for Refractory Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Obecabatagene autoleucel in Multiple Sclerosis, Chronic Progressive: NCT07139743 Clinical Landscape Report 2026
15 October 2026
NCT07139743 clinical landscape for Multiple Sclerosis, Chronic Progressive: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
BCD-256 in Systemic Lupus Erythematosus: NCT07136389 Clinical Landscape Report 2026
15 October 2026
NCT07136389 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
GT-719 in Idiopathic Inflammatory Myopathies: NCT07132112 Clinical Landscape Report 2026
15 October 2026
NCT07132112 clinical landscape for Idiopathic Inflammatory Myopathies: endpoints, sponsor, phase, geography, readouts, asset context and development white sp…
9 min read
Dual-targeting BCMA/CD19 CAR-T(Ucello Therapeutics) in Multiple Myeloma: NCT07139509 Clinical Landscape Report 2026
15 October 2026
NCT07139509 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
HPB-092 in Relapsing acute myeloid leukemia: NCT07137637 Clinical Landscape Report 2026
15 October 2026
NCT07137637 clinical landscape for Relapsing acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
9 min read
Ruxolitinib in Acute Myeloid Leukemia: NCT07131059 Clinical Landscape Report 2026
15 October 2026
NCT07131059 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dimethyl fumarate in Multiple sclerosis relapse: NCT07138833 Clinical Landscape Report 2026
15 October 2026
NCT07138833 clinical landscape for Multiple sclerosis relapse: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Debio 4127 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
Debio 4127: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
SURIO-001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
SURIO-001: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
NTX-1024 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
NTX-1024: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
EO-2002 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
15 October 2026
EO-2002: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.